Synthetic Glucocorticoids Modulate Function of Neural Cells: Implications in Autoimmune Neurological Disorders

Oscar Gonzalez-Perez, Norma A. Moy-Lopez and Jorge Guzman-Muniz

University of Colima/Laboratory of Neuroscience, School of Psychology

Mexico

1. Introduction

Glucocorticoids are hormones synthesized from cholesterol in the cortex of adrenal glands. Synthetic glucocorticoids are chemical derivatives synthesized from cholic acid obtained from cattle or steroid sapogenins. The chemical structure of these drugs is very similar to that of natural glucocorticoids. Therefore, the synthetic derivatives efficiently bind to intracellular receptors of glucocorticoid and mineralocorticoid, which promote a myriad of transcriptional and non-transcriptional processes. Synthetic glucocorticoids can trigger a cascade of events including neurotransmitter modulation, protein expression, neuronal firing or neurite growth. In addition, these substances are some of the most potent antiinflammatory and immunosuppressive agents available in human medicine with a good drug safety profile in humans. Thus, they are a valuable pharmacological tool for the treatment of acute and chronic neuroinflammation, and autoimmune disorders with neurological involvement. However, increasing evidence indicates that a high-dose or a long-term delivery of synthetic glucocorticoids may promote cognitive dysfunction, memory impairment, apoptosis, systemic hypersensitivity, urticaria-angioedema, neuronal degeneration, cerebral atrophy, major depression or steroid psychosis. Yet, these major side effects are relatively infrequent, the unrestricted use of glucocorticoids has to be avoided and systematic neuropsychological assessments are recommended to detect early neurological impairment. Herein, we discuss the mechanisms by which synthetic glucocorticoids may induce neural degeneration and other pathological changes in different brain regions. In addition, we describe the role of glucocorticoids in some autoimmune neurological disorders.

2. Glucocorticoids

The hypothalamus-pituitary-adrenal axis exerts an important regulation on neural functions mediated by the releasing of steroid molecules named corticosteroids. These hormones are synthesized from cholesterol in the cortex of adrenal glands (Fietta et al., 2009; Nicolaides et al., 2010). Two types of corticoids have been identified: glucocorticoids and mineralocorticoids. Glucocorticoids are produced in the inner region of the adrenal cortex (fascicular zone), while mineralocorticoids are synthesized in the outer part of the adrenal
cortex (glomerular zone) (Schimmer & George 1998). The name mineralocorticoid derives from early observations that associated these hormones with the homeostasis of sodium and water, whereas glucocorticoids obtained their name from initial observations that these steroids were involved in the metabolism of glucose. To date, it is well accepted that glucocorticoids and mineralocorticoids have a number of pleiotropic and systemic effects (Figure 1) on the cardiovascular system (Schimmer & George 1998; Ullian 1999), erythropoiesis (Amylon et al. 1986; King et al. 1988), calcium and bone metabolism (Thacker 2010), gastrointestinal tract (Black 1988), nitrogen excretion and glucose metabolism (Schimmer & George 1998), and exert a strong regulation in the immune system (Silverman et al. 2005). These physiological properties of glucocorticoids are useful in clinical medicine to treat and control a broad spectrum of diseases, such as: allergies, autoimmune diseases, cancer, hormonal replacement, asthma and sepsis. Nevertheless, glucocorticoids also have potentially harmful effects on several body systems, including the central nervous system. Some of these neurological impairments will be discussed below.

Fig. 1. Physiological effects of glucocorticoids and the hypothalamus-pituitary-adrenal axis. CRF = corticotropin-releasing factor; ACTH = adrenocorticotrophin hormone; (+) indicates stimulation and (-) indicates inhibition.

3. Synthetic glucocorticoids

Synthetic glucocorticoids are usually synthesized from cholic acid obtained from cattle or steroid sapogenins found in plants. The chemical structure of these drugs is slightly different from that of natural glucocorticoids (Figure 2 A - B). For example, prednisolone
differs from cortisol only by a δ-1-dihydro configuration. Instead, bexamethasone and betamethasone have additional 9-α-fluoro and 16-β- or 16-α-methyl groups, respectively (Tegethoff et al. 2009).

Fig. 2. Chemical structures of glucocorticoids. A. Metabolic pathways in the adrenocortical hormone biosynthesis. B. Synthetic glucocorticoids with anti-inflammatory and immunosuppressive activity.

Endogenous and synthetic glucocorticoids regulate a number of physiological and behavioural responses via intracellular receptors, which modulate the function of neural cells. In several brain regions, neural cells express two types of corticoid receptors: Type-1 receptors, also called mineralocorticoid receptors (MRs), and Type-2 receptors, also called glucocorticoid receptors (GRs) or NR3C1 (nuclear receptor subfamily 3, group C, member 1) (Fietta et al. 2009; Hoppmann et al. 2010; Marques et al. 2009; Prager et al. 2010). NR3C1
mediates the negative feedback in the HPA axis and in other limbic structures (de Kloet 2003; De Kloet et al. 1998). GRs have tenfold lesser affinity for corticosteroids than MRs (Table 1). The physiological outcome of these interactions is that GRs are mainly active during periods of abundant glucocorticoid secretion, such as circadian peak, systemic inflammation or stress. Thus, some of the functions of GRs include the regulation of energy metabolism, cellular homeostasis, stress-induced response, information storage and retrieval (de Kloet 2003; de Kloet et al. 1998). In contrast, MRs have a high affinity for corticosteroids; as a result, they are active when circulating glucocorticoid levels are relatively low. These receptors are highly expressed in hippocampus, septum, amygdala, frontal cortex, hypothalamic paraventricular nucleus and locus coeruleus (de Kloet 2003; De Kloet et al. 1998). One of the main functions of MRs is the regulation of basal HPA tone (de Kloet 2003; De Kloet et al. 1998).

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>11β-HSD1</th>
<th>11β-HSD2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular mass</td>
<td>34 kDa</td>
<td>40 kDa</td>
</tr>
<tr>
<td>Activity (Km)</td>
<td>Low affinity</td>
<td>High affinity</td>
</tr>
<tr>
<td>Cortisol: 17 mM</td>
<td>Cortisol: 12 nM</td>
<td></td>
</tr>
<tr>
<td>Corticosterone: 20 mM</td>
<td>Corticosterone: 45 nM</td>
<td></td>
</tr>
<tr>
<td>Cortisone: 200 mM</td>
<td>Dexamethasone: 140 nM</td>
<td></td>
</tr>
</tbody>
</table>

Table 1. Glucocorticoid affinity in type-1 (11β-HSD1) and type-2 receptors (11β-HSD2). Modified from Buckingham 2006.

<table>
<thead>
<tr>
<th>Glucocorticoid</th>
<th>Plasma half-life</th>
<th>Potency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cortisol</td>
<td>Short</td>
<td>0.8</td>
</tr>
<tr>
<td>Hydrocortisone</td>
<td>t1/2 8-12 h</td>
<td>1</td>
</tr>
<tr>
<td>Cortisone</td>
<td></td>
<td>0.8</td>
</tr>
<tr>
<td>Deflazacort</td>
<td>Intermediate</td>
<td>5</td>
</tr>
<tr>
<td>Prednisone</td>
<td>t1/2 12-36 h</td>
<td>4</td>
</tr>
<tr>
<td>Prednisolone</td>
<td></td>
<td>4</td>
</tr>
<tr>
<td>Methylprednisolone</td>
<td></td>
<td>5</td>
</tr>
<tr>
<td>Triamcinolone</td>
<td></td>
<td>5</td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>Long</td>
<td>25</td>
</tr>
<tr>
<td>Betamethasone</td>
<td>t1/2 36-72 h</td>
<td>30-40</td>
</tr>
</tbody>
</table>

Table 2. Potency and plasma half-life of natural and synthetic glucocorticoids commonly used in medicine.

The pharmacological effects of natural and synthetic glucocorticoids are mediated by the same genomic and non-genomic pathways (Buckingham 2006; Lowenberg et al. 2005; Lowenberg et al. 2006). The levels of efficacy, potency and pharmacological activity of synthetic hormones are determined by their pharmacokinetic properties (Table 2) (Fietta et al. 2009; Gonzalez-Perez et al. 2007). In clinic, synthetic glucocorticoids are commonly used as anti-inflammatory drugs for the treatment of allergies, rheumatic diseases, asthma, lymphoproliferative diseases and autoimmune disorders (Liberman et al. 2010). Most, if not all, of them can bind to both MRs and GRs, but with different affinities (Gonzalez-Perez et al. 2007). Remarkably, an increasing number of pre-clinical and clinical studies indicate that synthetic glucocorticoids can modify the citoarchitecture and function of glial cells, which alter the brain homeostasis.
Fig. 3. Astrocytes modulate and/or promote several effects into the brain under the influence of glucocorticoids. Corticoids (GCs); glucocorticoid receptor (GR); mineralocorticoid receptor (MR).
4. Effects of synthetic glucocorticoids on astroglia

GRs and MRs are expressed not only by neurons, but also by glial cells or neuroglia (Bohn et al. 1991; Vielkind et al. 1990). Glial cells are non-neuronal cells that preserve neural homeostasis, form myelin, and provide support and protection for neurons. In fact, corticoids exert several effects into the brain by targeting glial cells that, in turn, modify the cerebral functioning (Figure 3). Astrocytes, collectively known as astroglia, are the most abundant glial cells and play multiple roles into the brain, such as: Neurotransmitter reuptake and release, modulation of synaptic transmission, nervous system repair, hormonal signalling, vascular tone regulation, preservation of blood–brain barrier and, in some cases, astrocytes may function as neural stem cells (Gonzalez-Perez & Alvarez-Buylla 2011; Kettenmann & Ransom 2005).

Astroglia expresses the intermediate filament glial fibrillary acidic protein (GFAP), which is used as cellular marker of these cells (Ihrie & Alvarez-Buylla 2008). Interestingly, astrocytes contain high number of GRs and MRs; consequently, astrocyte function and their GFAP expression are highly susceptible to glucocorticoids (Lambert et al. 2000; Rozovsky et al. 1995). Some of the effects of glucocorticoids on gene and protein expression in astrocytes are summarized in the table 3.

<table>
<thead>
<tr>
<th>Protein / gene</th>
<th>Function</th>
<th>Glucocorticoid effect</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glial fibrillary acidic protein (GFAP)</td>
<td>Intermediate filament protein</td>
<td>Upregulation</td>
<td>(O’Callaghan et al. 1991; Ramos-Remus et al. 2002)</td>
</tr>
<tr>
<td>Glutamine synthetase</td>
<td>Neurotransmitter recycling</td>
<td>Upregulation</td>
<td>(Hansson 1989; Vardimon et al. 1999)</td>
</tr>
<tr>
<td>Basic fibroblast growth factor (bFGF)</td>
<td>Neurotrophic protein</td>
<td>Upregulation</td>
<td>(Niu et al. 1997)</td>
</tr>
<tr>
<td>S100β</td>
<td>Ca2+-binding neurotrophic protein</td>
<td>Upregulation</td>
<td>(Van den Hove et al. 2006)</td>
</tr>
<tr>
<td>N-myc downstream-regulated gene (Ndr2)</td>
<td>Cell differentiation</td>
<td>Upregulation</td>
<td>(Nichols et al. 2005)</td>
</tr>
<tr>
<td>Lipocortin-1</td>
<td>Anti-inflammatory protein</td>
<td>Upregulation</td>
<td>(McLeod &amp; Bolton 1995)</td>
</tr>
<tr>
<td>Nerve growth factor (NGF)</td>
<td>Neurotrophic protein</td>
<td>Downregulation</td>
<td>(Niu et al. 1997)</td>
</tr>
<tr>
<td>Vimentin</td>
<td>Intermediate filament</td>
<td>Downregulation</td>
<td>(Avola et al. 2004)</td>
</tr>
</tbody>
</table>

Table 3. Effects of glucocorticoids on protein and gene expression in astrocytes.

_in vitro_ administration of dexamethasone, corticosterone or aldosterone inhibits astrocyte proliferation in a dose-dependent manner (Crossin et al. 1997). This effect seems to be mediated by neural cell adhesion molecules, which inhibit activation of mitogen-activated protein (MAP) kinase (Krushel et al. 1998). The corticoid-induced inhibition of cell
proliferation and growth retardation may also be enhanced by a concomitant reduction in
the production of insulin-like growth factor 1 (IGF-1) in parenchymal astrocytes (Adamo et al. 1988). On the other hand, the overexpression of GFAP and chondroitin sulfate proteoglycans in reactive astrocytes has been related to a deficient neuronal repair and less
neurite outgrowth. Methylprednisolone can revert these adverse effects by downregulating
astrocyte activation (Liu et al. 2008) and reducing the number of GFAP-expressing astroglia
(Sabolek et al. 2006). Further studies indicate that dexamethasone can modify hippocampal
neuron development and survival by decreasing the mRNA levels of nerve growth factor
(NGF) (Niu et al. 1997) and GFAP in hippocampus and neocortex (Aleong et al. 2003). In contrast, other reports using corticosterone (Bridges et al. 2008), prednisone (Ramos-Remus et al. 2002) and deflazacort (Gonzalez-Castaneda et al. 2007) reported an increase in the
number and cytoplasmic processes of hippocampal and cortical astrocytes. The reason for
these discrepancies is not well-known, but they appear to be mediated by dose- and region-dependent phenomena (Gonzalez-Perez et al. 2001).

Glucocorticoids not only modify the function of glial cells in adult stages, but also during
prenatal development. Prenatal betamethasone administration delays both astrocyte and
capillary tight junction maturation (Huang et al. 2001a), as well as the myelination in the
corpus callosum (Huang et al. 2001b). Remarkably, glucocorticoid effects are not limited to
the modulation of cell morphology or molecular expression in neuroglia. Instead, they are
key modulators of glycogen metabolism and neurotransmitter transporter homeostasis as
demonstrated in several experimental models. For instance, cortical astrocytes exposed to
dexamethasone show a reduction of noradrenaline-induced glycogen synthesis (Allaman et al. 2004). Prednisolone, betamethasone and dexamethasone inhibit the transporter uptake of
monoamines producing effects on physiological and behavioral processes (Hill et al. 2010).
The glial glutamate transporter-1 (GLT-1) is also affected by synthetic glucocorticoids. In
cortical astrocytes, dexamethasone provokes a marked increase in the GLT-1 transcription
and GLT-1 protein levels (Zschocke et al. 2005). GABAergic neurons are also affected by
synthetic glucocorticoids that impair their rhythmic firing, which may lead to cognitive
deficit (Hu et al. 2010). Taken together, this evidence indicates that synthetic glucocorticoids
exert a strong modulation on neural cells by modifying protein expression, neurite growth,
cell proliferation, neurotransmitter uptake, neuronal firing, vasculature function and
neuronal degeneration.

4.1 Implications in autoimmune neurological disorders. Pathological features
observed in patients upon GCs administration
One major application of synthetic glucocorticoids is the treatment of acute and chronic
neuroinflammatory disorders, such as multiple sclerosis, autoimmune encephalomyelitis,
immune rejection, Parkinson’s disease, retinal degeneration and others. Increasing evidence
indicates that the therapeutic efficacy of glucocorticoids against autoimmune disorders may
rely not only on their well-known anti-inflammatory effects, but also on their properties of
neuro-gliomodulation (Gonzalez-Perez et al. 2007). For instance, methylprednisolone has a
synergistic effect with Nogo-66 receptor protein, which promotes functional recovery and
axonal growth in a model of spinal cord contusion (Ji et al. 2005). Methylprednisolone also
mediates anti-apoptotic effects on oligodendrocytes by activating STAT5 proteins, which
up-regulate a splicing isoform of the bcl-x gene (Xu et al. 2009). On the other hand,
prednisone contributes to attenuate experimental autoimmune encephalomyelitis by
preventing the reduction of brain-derived neurotrophic factor (BDNF) and NGF mRNA
expression into the brain (Chen et al. 2009). Promising results have also been obtained with dexamethasone and fluocinolone in several studies, i.e. dexamethasone reduces astroglial reactivity to implanted neuropsychosthetic devices in rat cortex (Spataro et al. 2005), whereas intravitreous administration of fluocinolone attenuates retinal degeneration (Glybina et al. 2010). Further evidence suggests that dexamethasone produces immunosuppressive effects on the astrocyte response to interleukin-1-beta stimulation (Pousset et al. 1999) and counteracts blood-brain barrier failure by decreasing transendothelial permeability (Cucullo et al. 2004).

Despite synthetic glucocorticoids have demonstrated an adequate safety profile, increasing clinical experience and experimental studies indicate that corticoids are able to promote cognitive dysfunction, anxiety, cerebral atrophy, depression and steroid psychosis. One of the first studies that associated the glucocorticoid delivery with mood disorders in humans was reported in prednisone-treated asthmatic children (Bender et al. 1991). However, adults are also affected by corticoids as demonstrated in healthy volunteers that, after receiving a high-dose prednisone or dexamethasone, showed mood changes and memory impairment (Keenan et al. 1996; Schmidt et al. 1999; Wolkowitz 1994). Cerebral atrophy was reported after a long-term treatment with glucocorticoids in patients with no previous history of central nervous system affection (Bentzon et al. 1978; Hara et al. 1981). Other immunologic disorders, such as systemic corticosteroid hypersensitivity (de Sousa et al. 2010; Rachid et al. 2011), toxic epidermal necrolysis (Navarro Llanos et al. 1996) or urticaria-angioedema (Gomez et al. 2002), have also been associated with the administration of glucocorticoids. Under specific circumstances synthetic corticoids may impair or even potentiate the progress of neurological disorders as reported in experimental models of Alzheimer’s disease, hypoxia or prenatal glucocorticoid delivery. This fact appears to be particularly important in neurodegenerative disorders related to oxysterol production such as Alzheimer’s disease and multiple sclerosis. Oxysterols are oxidized forms of cholesterol that provokes oligodendrocyte apoptosis. Dexamethasone exacerbates the apoptotic effects of oxysterols on oligodendrocytes, resulting in secondary necrosis (Trousson et al. 2009). Cerebral vasculature is also altered by exposure to dexamethasone that may deteriorate hippocampal functions (Neigh et al. 2010). In hypoxia models, dexamethasone increases the expression of Bnip3, a pro-apoptotic Bcl-2 family, which impairs hypoxic tissue damage (Sandau & Handa 2007).

Neuronal function and survival are also affected by synthetic corticoids. Dexamethasone increases oxidative stress and expression of monoamine oxidase A and B, resulting in a higher loss of dopaminergic neurons (Arguelles et al. 2010). Oral administration of prednisone or deflazacort promotes neuronal degeneration of pyramidal neurons in CA1 and CA3 hippocampal regions (Gonzalez-Castaneda et al. 2007; Gonzalez-Perez et al. 2007; Ramos-Remus et al. 2002). Dexamethasone also decreases the number of neurons in the striatum (dorsomedial caudate-putamen) and hippocampus (dentate gyrus, CA1 and CA3 subfields), which may account for some of the cognitive deficits seen following administration of glucocorticoids to healthy volunteers (Haynes et al. 2001). Glucocorticoids also target the developing brain as reported in children exposed to synthetic glucocorticoids in utero, who showed a reduction in fetal and, in some cases, newborn and infant HPA axis activity (Tegethoff et al. 2009). Other studies indicate that prenatal dexamethasone exposure also affects postnatal cognitive functions (Hauser et al. 2007; Hauser et al. 2006), reduces the survival of cholinergic neurons (Emgard et al. 2007), and produces permanent changes in the cytoarchitecture within midbrain dopamine nuclei (McArthur et al. 2005).
Taken together, this evidence indicates that synthetic glucocorticoid may have detrimental effects on glial and neuronal integrity. Therefore, some authors have proposed that uncontrolled use of glucocorticoids may predispose to the development of a range of psychiatric and neurological conditions throughout life.

5. Conclusion

Synthetic glucocorticoids are a valuable therapeutic strategy against neuroinflammation and autoimmune disorders with neurological involvement. In fact, anti-inflammatory strategies receive growing attention for their potential to prevent pathological deterioration in multiple sclerosis (the most prevalent chronic autoimmune disease of the central nervous system), Parkinson's disease, autoimmune encephalomyelitis and other severe neurological disorders. Nevertheless, the uncontrolled use of glucocorticoids must be avoided because of their deleterious potential on cognition, neuronal survival and apoptosis induction. Yet, in those clinical situations where glucocorticoid use is necessary, a continuous neuropsychological assessment is strongly recommended to detect a possible neurological deterioration.

6. Acknowledgments

This work was supported in part by grants from the Consejo Nacional de Ciencia y Tecnología’s (CB-2008-101476) and the National Institute of Neurological Disorders and Stroke (NIH R01 NS070021-01).

7. References


Synthetic Glucocorticoids Modulate Function of Neural Cells: Implications in Autoimmune Neurological Disorders


Tegethoff, M., Pryce, C., & Meinschmidt, G. (2009). Effects of intrauterine exposure to synthetic glucocorticoids on fetal, newborn, and infant hypothalamic-pituitary-


Autoimmune disorders are caused due to breakdown of the immune system, which consequently fails in its ability to differentiate "self" from "non-self" in the context of immunology. The diseases are intriguing, both clinically and immunologically, for their diversified clinical phenotypes and complex underlying immunological mechanisms. This book offers cutting-edge information on some of the specific autoimmune disease phenotypes, respective diagnostic and prognostic measures, classical and new therapeutic options currently available, pathogenesis and underlying mechanisms potentially involved, and beyond. In the form of Open Access, such information is made freely available to clinicians, basic scientists and many others who will be interested regarding current advances in the areas. Its potential readers will find many of the chapters containing in-depth analysis, interesting discussions and various thought-provoking novel ideas.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following: